


2023 highlights

Academic inventions – from science to market



From science towards market..

Highlights 2023

After a thorough selection process in 2022, we presented in 2023, for the first time, the Utrecht Holdings Innovation Vouchers to the following projects:



- A device for non-invasive monitoring of heart failure patients. The team developed a prototype device connected to an app.
- A hydrogel for drug delivery in ocular therapy. Researchers expanded the variety of drugs that can be captured in the hydrogel which strengthened patent claims.
- A delivery system for tumor antigens using nanoparticles. During the project, structure characterization was performed which added value to patent claims.
- Antiviral peptides that bind to SARS-CoV-2 and neutralize the virus. The team synthesized a high-quality peptide batch for reliable follow up studies.

License agreements



Orgonex is developing proprietary bioreactor technology which holds great promise in the field of organoid culture for regenerative medicine purposes.

AYUVANT

Ayuvant is a pharmaceutical company that created an advanced delivery system to boost the reach of RNA medicines



Amotio BV develops a device was invented for removing orthopedic bone cement during implant revision surgery.

Other license agreements signed in 2023: PrecorDX Cordys

Cordys analytics





Preimure



Utrecht Holdings Impact 2023

...and Venture funding & support Highlights 2023



Cordys Analytics – 900K first investment

for further development of their Al-powered software platform for early and improved detection of heart disease. Cordys Analytics' Al-powered software platform for ECG analysis offers a solution to detect heart disease earlier and more accurately. Using Al, this software identifies subtle patterns and abnormalities in ECG data that traditional diagnostic methods often miss.

Investors: Utrecht Health Seed Fund, ROM Regio Utrecht and LUMO Labs.

Utrecht Health Seed Fund has closed...

EUR 5.4 M was invested in 11 companies over three years. In 2023, first investments were made in Phlox Therapeutics, Cordys Analytics, Ascenscia, Synerkine Pharma and Cryocloud. Several follow-up investments were also made. **New UHSF will be launched in 2024 !...**



ASCENSCIA

Ascenscia – Seed Round

EUR 300K+ to develop their highly specialized voice-assistant for scientific labs that integrates seamlessly with existing lab systems. Utrecht Health Seed fund and imec.istart participated in this round.



Phlox Therapeutics – Seed Round

EUR 900K to advance their lead program aimed at rare genetic laminopathies to preclinical development. INH, AMC Ventures Holding, FIRST and UHSF joined this round.




Synerkine Pharma – Series A

EUR 12.1 M to develop their cytokine fusion protein to combat complex regional pain syndrome. The round was led by Flerie and joined by UHSF and InnovationQuarter as well as existing investor Thuja Capital.

And also..

We launched our new website where you can clearly find the path to be followed te create impact. Let's team up!





Champions event

Impact

Check

In June, Utrecht Holdings organized the first Champions lunch!

As champion of knowledge transfer, you will be able to support other scientists in advancing their inventions to society. By referring them to Utrecht Holdings, we will be able to seize more business opportunities together. Let's team up! We trained > 570 scientists On Intellectual Property, commercialization of science, how to collaborate with industry, and how to spin out a venture from academia. We did this amongst others in an online version of our program 'Selling Your Science'. **Utrecht Holdings team !**



UTRECHT HOLDINGS

Utrecht Holdings

Heidelberglaan 8, kamer 0,43 3584 CS Utrecht The Netherlands secretariaat@utrechtholdings.nl

UTRECHT HEALTH SEED FUND

Utrecht Health Seed Fund

Heidelberglaan 8, kamer 0,43 3584 CS Utrecht The Netherlands contact@uhsf.nl